Sathgen Therapeutics, a division of India's leading chemical conglomerate, Godavari Biorefineries Limited has announced the completion of the first cohort of a Phase 1 clinical trial for its first-in-class new chemical entity, MSP008-22. The clinical trial program is managed by Clinexel Life Sciences, a renowned contract research organization in the healthcare industry.

Sathgen Therapeutics aims to develop MSP008-22 for hard-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate cancer as proof of principle. MSP008-22 effectively targets treatment-resistant cancer cells in preclinical models and exhibits an excellent safety profile, with no serious adverse effects, in the first cohort of patients.

Professor Sendurai Mani, Associate Director of Brown University's Legorreta Cancer Center and Scientific Co-Founder of Sathgen Therapeutics, said: “TNBC is responsible for 30% of breast cancer deaths.  The absence of estrogen and progesterone receptors and the expression of HER2 make it a difficult cancer to treat with conventional hormone therapy. The MSP008-22 will address this important unmet need for patients with TNBC. »

Sangeeta Srivastava, Executive Director of GBL and Scientific Director of Sathgen Therapeutics, added:  “This clinical trial is an important milestone for us, as it marks the entry of our first program into clinical development. MSP008-22 is our lead candidate for the treatment of breast cancer and prostate cancer, and it improves the efficacy of standard chemotherapy. »

Dr. Samir Somaiya, Chairman of GBL and Executive Co-Founder of Sathgen Therapeutics, emphasized: “At GBL, research is the cornerstone of our business, which continuously creates value for society. We are dedicated to discovering new medicines to generate lasting benefits. This trial represents a critical step in our mission to help patients with hard-to-treat cancers. »

Deepa Arora, CEO of Clinexel, explained:  “The success of the first cohort of this study (NCT05478486) in patients with advanced solid tumors, without any adverse effects, is very encouraging. We are working to develop a safe and effective oral treatment for patients with breast or prostate cancer. »

Sathgen Therapeutics focuses on the development and commercialization of new drugs to improve the lives of cancer patients. With more than 15 cancer drug candidates in development, Sathgen Therapeutics remains committed to advancing cancer treatments. To learn more, visit the website  https://sathgentherapeutics.com .

For collaboration or investment opportunities, please contact Sathgen Therapeutics at  BD@sathgentherapeutics.com  or  InvestorRelations@sathgentherapeutics.com . For more information, go to  www.clinicaltrials.gov .

 

Source:prnewswire.com

Report Abuse